Abstract

Humana will announce its second-quarter 2026 results on July 29, 2026 Pre-MKt; this preview synthesizes consensus forecasts, last-quarter performance, segment dynamics, and institutional views to frame the key drivers for revenue, margins, and adjusted EPS into the print.

Market Forecast

Consensus points to second-quarter 2026 revenue of 40.61 billion US dollars, up 27.33% year over year, with adjusted EPS at 7.22, implying 21.97% year-over-year growth, and EBIT at 1.37 billion US dollars, up 17.92% year over year. No specific consensus forecast is available for quarterly gross profit margin or net profit margin.

Humana’s core revenue base remains tied to its insurance operations, where elevated medical-cost utilization and benefit-ratio discipline are the central near‑term variables; recent transformation initiatives are intended to align costs and operating model with market conditions. Within the disclosed breakdown, revenue from external customers was 39.39 billion US dollars last quarter, while investment income was 0.26 billion US dollars; segment-level year-over-year growth data was not provided.

Last Quarter Review

Last quarter, Humana delivered revenue of 39.65 billion US dollars, gross profit margin of 14.98%, GAAP net profit attributable to the parent of 1.19 billion US dollars, a net profit margin of 2.99%, and adjusted EPS of 10.31, down 10.97% year over year, while revenue rose 23.47% year over year.

A key highlight was modest outperformance versus consensus: revenue surpassed the Street by roughly 0.72%, and adjusted EPS topped estimates by about 0.12 per share. By revenue source, external customers contributed 39.39 billion US dollars (approximately 99.34% of total) and investment income 0.26 billion US dollars; year-over-year segment growth was not disclosed in the company’s breakdown.

Current Quarter Outlook

Core insurance operations into Q2 2026

The quarter’s narrative for Humana centers on utilization, benefit-ratio management, and the interplay between claims trends and pricing. Consensus anticipates revenue growth of 27.33% year over year to 40.61 billion US dollars, which implies continued momentum in premium flows and membership, offset by a sequentially lower adjusted EPS profile at 7.22 relative to last quarter’s 10.31. The sequential step-down in EPS is consistent with the company’s emphasis on absorbing medical-cost intensity as it realigns benefits and costs while executing its multiyear transformation program.

Management has flagged that lower Medicare Advantage Star Ratings will weigh on earnings in 2026, and investors should expect the benefit ratio to remain a dominant driver of margin cadence through the year. Last quarter’s insurance-segment benefit ratio was cited externally at 89.4%, which was a fractional beat versus market expectations and indicates some discipline in claims costs; as a result, consensus expects EBIT of 1.37 billion US dollars this quarter, a 17.92% year-over-year increase, even as the environment remains cost-aware. With gross and net margin forecasts not specified by consensus, the most tangible signals for this quarter’s margins are likely to come from commentary on claims mix (inpatient vs. outpatient), specialty drug trends, and any incremental impact from benefit design adjustments.

Operating expense containment and transformation charges are second-order levers across the quarter. The company continues to incur restructuring-related costs, including severance, asset impairments, and external consulting, with the stated goal of re-aligning its cost structure and technology footprint. For the quarter at hand, investors will parse whether cost actions are progressing on schedule and whether expense timing (including commercial and administrative costs tied to member services) is tracking to plan. Given that last quarter’s net profit rebounded sharply quarter over quarter, Humana’s ability to sustain normalized run-rate profitability while navigating cost headwinds will be scrutinized closely as a read-through to second-half earnings quality.

Medicare Advantage trajectory and pricing tailwinds

Although the immediate quarter remains governed by medical-cost utilization and 2026 Star Ratings headwinds, recent policy outcomes for 2027 have become an important backdrop for sentiment. Multiple institutions highlighted that finalized 2027 Medicare Advantage rate dynamics were better than expected, and that a proposed risk-model change was dropped, which collectively reduces a major overhang on forward margins. Those developments do not directly alter Q2 2026 results, but they inform management tone and investor reaction to any commentary on the forward benefit ratio and plan pricing strategy for the next bid cycle.

From a revenue structure standpoint, the disclosed main-business breakdown last quarter shows 39.39 billion US dollars from external customers and 0.26 billion US dollars from investment income. While this disclosure is at a high level, it helps frame that core premium and service revenue, not investment income, will carry the top line this quarter. As investors evaluate the “most promising” path to earnings normalization beyond 2026, analysts are now more open to the view that Medicare Advantage margin recovery can resume under a more stable rate and risk-adjustment backdrop. Near term, this quarter’s print will be assessed for signs that utilization is not worsening, that benefit design calibrations are taking hold, and that administrative actions are tightening expense trends without disrupting service quality.

Humana’s transformation program is also relevant to forward Medicare Advantage profitability. The company’s intent to streamline the operating model and modernize its technology should support faster benefit-design responsiveness and claims management efficiency. As these initiatives scale, even small improvements in claim adjudication speed, prior-authorization workflows, and provider network effectiveness can accrue to margin. The quarterly update is therefore expected to offer clarity on execution milestones, which factor into analyst confidence levels for out-year recovery trajectories.

Key swing factors for the stock around the print

The single largest swing factor remains the medical-cost trend. If claims intensity, especially among older members, stabilizes or decelerates compared with the first quarter run-rate, the setup for EPS could improve relative to consensus. Conversely, any evidence of higher inpatient admissions, procedure volumes, or expensive specialty drug utilization could bring downside risk to adjusted EPS, even with strong revenue delivery. Investors will listen for granular color on utilization by service category and age cohort to triangulate directionality for the second half.

A second swing factor is management’s commentary on the full-year earnings outlook and the progression of its transformation program. The company reiterated a full-year adjusted earnings framework previously, while trimming non-adjusted guidance due to transformation costs; reaffirmation and specificity on cadence into the back half of 2026 would be supportive. The Street will weigh whether Humana articulates incremental cost saves, timing of technology and workflow consolidation, and any early quantitative benefits that may offset the 2026 Star Ratings headwinds.

Capital structure actions and selective portfolio moves are a third variable. The recent issuance of 1.00 billion US dollars of junior subordinated notes with a bbb- issue credit rating and a stable outlook provides additional flexibility and liquidity. Investors will look for updates on intended use of proceeds, repayment plans for shorter-term borrowings, and the company’s appetite for further portfolio optimization following minority-stake moves. Balance-sheet flexibility can matter at the margin for valuation if investors gain confidence that capital allocation remains both selective and attuned to earnings durability.

A final, supportive factor for sentiment has been policy clarity and peer signals. News flow during the quarter indicated stronger-than-feared 2027 Medicare Advantage rate decisions, which materially shifted institutional expectations for margin recovery in that year, and more recently, a peer’s print helped improve payer-sector sentiment. For this quarter’s call, the key is less about explicit 2027 guidance and more about whether management’s tone around utilization, benefit design, and expense trajectory aligns with the improved policy backdrop and enables investors to bridge to a cleaner 2027 earnings path.

Analyst Opinions

The balance of institutional commentary skews positive heading into Humana’s second-quarter report, with the majority expressing constructive or outright bullish views versus a smaller minority maintaining a bearish stance; across published updates since June, the bullish-to-bearish ratio is approximately 5:1 based on target-price increases, one upgrade, and one notable underweight call.

Bernstein reiterated an Outperform rating and lifted its price target to 425, emphasizing a path toward margin normalization as policy risks eased and execution on cost realignment progresses. The firm’s stance reflects rising confidence that the combination of disciplined benefit design, stabilization in utilization, and administrative efficiencies can re-expand operating margins beyond the trough implied by 2026 Star Ratings. In Bernstein’s framing, the policy outcome for 2027 effectively pulled a significant risk lever off the table, creating room for the market to look through near-term EPS fluctuations if claims trends do not deteriorate further.

Wells Fargo upgraded Humana from Underweight to Equal Weight and raised its price target to 227, explicitly citing better-than-expected 2027 Medicare Advantage rates and the removal of a proposed risk-model change that had been an overhang. The team also lifted 2027 profit estimates by roughly 27% and argued that a meaningful portion of out-year earnings can be driven by the recovery in Medicare Advantage margins. While Equal Weight is neutral on rating, the upgrade and estimate revisions are directionally supportive of a constructive outlook into and beyond this quarter.

RBC Capital Markets raised its target to 415 while maintaining Sector Perform, noting improved visibility on forward rates and a more balanced risk-reward given the sell-off earlier in the year. RBC’s stance underscores that, even without a formal rating change to Outperform, the target increase reflects higher conviction that downside tail risks have moderated and that execution on cost initiatives could allow the company to close part of its valuation gap if claims stabilize. Similarly, Truist lifted its price target to 415 while keeping a Hold rating, arguing that near‑term utilization uncertainty is offset by a cleaner policy setup into 2027, which helps bolster confidence in longer-term margin repair.

BofA Securities also increased its target to 380, a move that aligns with the cluster of upward target revisions across the sell side following the finalization of 2027 Medicare Advantage rates. Though the firm’s explicit rating was not reiterated in the referenced update, the directional change in target supports the broader theme that the Street is shifting from a pure risk-management posture to cautiously rebuilding upside cases. Evercore ISI raised its target to 370 and maintained an In Line rating, adding to the consensus that the policy trajectory has moved favorably and that the main gating factor for upside is claims trend stabilization rather than structural rate pressure.

In aggregate, the prevailing sell-side narrative ahead of the quarter emphasizes: 1) the likelihood that Q2 results are still governed by utilization and benefit-ratio management; 2) improving confidence in the 2027 margin trajectory as policy headwinds abate; and 3) a view that execution on cost transformation can underpin earnings quality once the Star Ratings impact rolls through the P&L. The market will anchor on this quarter’s signals around medical-cost intensity and management’s color on the second half, but the institutional tilt is that recent policy clarity substantially improves the medium-term setup, leaving the shares more levered to the cadence of utilization moderation than to further policy shocks.